Skip to main content
. Author manuscript; available in PMC: 2014 Jul 10.
Published in final edited form as: Ann Surg Oncol. 2008 Nov 1;16(1):186–190. doi: 10.1245/s10434-008-0187-5

FIG. 1.

FIG. 1

DSS in patients with a positive and negative NSLN. Median survival in the NSLN– group was 104 months, while median survival in the NSLN+ group was 36 months (p < 0.001)